A study of dapagliflozin found that it increased HDL cholesterol without significantly affecting LDL cholesterol.[14] Results of the meta-analysis[15,16] of SGLT2 inhibitors treatment for type 2 diabetes mellitus confirmed that SGLT2 inhibitors, including empagliflozin and dapagliflozin, could increase the levels of LDL and HDL cholesterol. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.